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Abstract  
Celiac disease (CD) is an autoimmune entero- pathy, characterized by an inappropriate T-cell-mediated immune response 
to the ingestion of certain dietary cereal proteins in genetically susceptible individuals. This disorder presents 
environmental, genetic, and immunological com- ponents. CD presents a prevalence of up to 1% in populations of 
European ancestry, yet a high percentage of cases remain underdiagnosed. The diagnosis and treatment should be 
made early since untreated disease causes growth retardation and atypical symptoms, like infertility or neurological 
disorders. The diagnostic criteria for CD, which requires endoscopy with small bowel biopsy, have been changing over the 
last few decades, especially due to the advent of serological tests with higher sensitivity and specificity. The use of 
serological markers can be very useful to rule out clinical suspicious cases and also to help monitor the patients, after 
adherence to a gluten-free diet. Since the current treatment consists of a life-long gluten- free diet, which leads to 
significant clinical and histological improvement, the standardization of an assay to assess in an unequivocal way gluten in 
gluten-free foodstuff is of major importance. 
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ELISA enzyme-linked immunosorbent assay  
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Introduction 
 
Celiac disease (CD) is a disorder of the small intestine 
caused by an inappropriate immune response to wheat 
gluten and similar proteins of barley and rye in 
genetically susceptible individuals. CD can be also 
referred to as celiac sprue, nontropical sprue, gluten-
sensitive enteropathy, or idiopathic steatorrhea [1]. The 
classic presentation, with malabsorption, was first 
described by Samuel Gee in 1888 [2], but the relation 
between the disease and wheat was not reported until 
the late 1940s by Willem Karel Dicke,   who 
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observed that the ingestion of certain cereal grains was 
harmful to children with celiac disease [2, 3]; later, John W 
Pauley described the associated histologic changes in the 
intestine [4]. 
CD is found mainly in Caucasians, occurring in 1 per 
130–300 individuals in the western European population 
[5–7]. Although CD is one of the most common immune- 
mediated disorders, there still remains a considerable 
prevalence of undetected cases [8]. 
It is more appropriate to consider CD as a multisystem 
disorder, rather than mainly gastrointestinal. A 
considerable number of conditions are associated with 
CD, namely osteoporosis, malignancy, and infertility. It is 
also associated with other autoimmune disorders, such as 
dermatitis herpeti- forms, type 1 diabetes, or autoimmune 
thyroiditis, and with neurological and genetic disorders [4, 
9–12]. 
 
 
Clinical presentation 
 
Celiac disease can be diagnosed at any age; however, 
it presents most commonly in early childhood (between 9 
and 24 months) or in the third or fourth decade of life 
[13–16]. As occurs in other autoimmune disorders, CD is 
more common in females than in males at a ratio of 3 to 1 
[17]. Although, it is a disorder that primarily affects the 
small bowel, the symptoms can range from classic 
gastrointesti- nal symptoms, such as diarrhea and 
abdominal distension, which are more common in infants 
and young children, to nonspecific gastrointestinal 
symptoms and extraintestinal manifestations, typical of 
older age groups; moreover, some patients are 
asymptomatic [8, 18]. The concept of the “celiac iceberg” 
has been used to emphasize the clinical variability  of 
celiac disease and  that  many  cases  are still 
undiagnosed [10]. 
The clinical presentation of CD is, therefore, very 
heterogeneous, ranging from an asymptomatic or silent 
stage to a clinically overt or symptomatic form [19]. The 
asymptomatic forms are characterized by extraintestinal 
symptoms, but with typical histological changes and 
positive serology. The classic or symptomatic form 
presents typical gastrointestinal symptoms, histological 
changes, and positive serology. 
The term “latent” CD characterizes the subjects with 
genetic predisposition to develop CD. They do not have a 
flat mucosa, despite a gluten-containing diet, but 
probably will develop clinically overt CD later in life [20–
22]. These patients usually present increased 
intraepithelial lympho- cytes (IELs) and positive serology 
for endomysial anti- bodies (EMA) and tissue 
transglutaminase (tTG) antibodies with HLA-DQ2 or DQ8 
predisposing genotype [23–25]. 
Finally, the term “refractory” CD refers to patients who 
do  not  respond  to  a  gluten-free  diet  or  who previously 
 responded but later became nonresponsive, presenting 
severe villous atrophy despite maintenance of a strict 
gluten-free diet [26]. 
The severity of symptoms is not necessarily propor- 
tional to the severity of the mucosal lesions. In fact, 
currently, there are more subjects with asymptomatic or 
mild celiac disease than with the classic symptoms of 
severe  malabsorption  [3, 21]. 
 
 
Genetics and pathogenesis 
 
The disease is genetically determined, affecting 10% of 
first-degree relatives and 75% of the monozygotic 
twins being both affected. The human leucocyte antigen 
HLA- DQ2 is presented in 90–95% of CD patients and the 
remaining 5–10% of patients are HLA-DQ8 positive [18]. 
Although the possession of the HLA proteins is 
necessary, it is not sufficient for CD development, since 
about 30% of the healthy population possess them [27–
29]. 
Gluten is a complex mixture of wheat storage 
proteins that can be alcohol-soluble fractions, the 
gliadins, and alcohol-insoluble fractions, the glutenins 
[28]. Based on their differential N-terminal sequence, 
size, and electropho- resis mobility [30] gliadins are 
subdivided into α, β, γ, and ω-gliadins. Glutenins consist 
of low molecular weight (LMW) and high molecular 
weight (HMW) glutenins [31]. Gliadins are also called 
prolamins due to their high content of the amino acids 
proline and glutamine. It is generally accepted that 
prolamins are the major triggering factors in CD [32]. 
Gliadins have analogous proteins that are present in 
barley (hordeins), rye (secalins), and oats (avenins). 
Recent studies failed to identify the toxic amino acid 
sequence in oats [33], which is considered toxic in 
only a minority of patients with CD  [18]. 
The mechanism underlying CD pathogenis can be 
explained by the ingestion of the alcohol-soluble 
protein components of wheat, barley, and rye. These 
gluten peptides are resistant to digestion by gastric and 
pancreatic enzymes due to their high content in proline, 
reaching the epithelial cell membrane and passing into 
the cytosol [34]. The deamidation of these proline-rich 
gluten peptides is mediated by tTG enzyme [35] creating 
epitopes with increased immunostimulatory potential. 
The deamidated epitopes are then presented, in 
association with the human leucocyte antigens DQ2 and 
DQ8 of antigen-presenting cells, to CD4+ T cells 
expressing α/β T cell receptor [36]. These T cells become 
activated and express proinflamma- tory cytokines [37] 
that, in turn, promote the release of matrix 
metalloproteinases which cause epithelial cell damage 
leading to the development of the flat mucosa, typical of 
CD [37]. The resulting tissue injury leads to further release 
of tTG [29]. 
  
 
 
The in vitro study by Lu Shan and colleagues [38] 
reported a highly stable 33-mer peptide, rich in proline 
and glutamine, which has been isolated from gliadin and 
is thought to contain the toxic sequence. This 33-amino-
acid peptide has been reported to have 
immunodominant characteristics, being resistant to 
degradation by all gastric, pancreatic, and intestinal brush 
border membrane proteases in the human intestine, and 
is readily available for T cell recognition and activation. 
 
 
Diagnosis and management 
 
The diagnosis of CD is complicated by the diversity of 
clinical manifestations that are related to the age at onset 
and symptomatology. 
 
Biopsy 
 
Diagnostic criteria for CD in both children and adults are 
still based on the guidelines proposed in 1990 by the 
European Society for Paediatric Gastroenterology and 
Nutrition (ESPGAN) [39]. Small bowel biopsy has been the 
standard diagnostic test for CD during the last 30 years. 
The biopsy is performed during an upper endoscopy 
and should only take place during a normal gluten-
containing diet, when villous atrophy and crypt 
hyperplasia can be detected. Multiple samples are taken 
from the second or third part of the duodenum. 
Inadequate sampling and patchy villous atrophy can lead 
to an incorrect diagnosis. Moreover, it should also be 
considered that isolated marked villous flattening and 
IELs can be found in other diseases [40]. 
Recently, there has been an increase in atypical forms 
of CD, including cases without significant gastrointestinal 
symptoms, and cases presenting symptoms and 
complications of CD before the development of villous 
atrophy [41, 42]. 
 
Biological markers 
 
Recent guidelines from the ESPGAN [39], and the North 
American Society for Pediatric Gastroenterology, Hepatol- 
ogy and Nutrition (NASPGHAN) [43] have suggested an 
algorithm for diagnosis (Fig. 1), in which the serological 
tests appear as the first test to clear clinical suspicion of 
celiac disease in patients presenting characteristic symp- 
toms or in those who belong to a risk group. These 
patients at risk are those with celiac disease-associated 
disorders, such as endocrine, neurological, liver, genetic, 
and autoim- mune diseases; first- and second-degree 
relatives of celiac patients are also at risk. 
Antibody tests cannot replace histological studies of 
bowel  biopsies;  however,  they  are  very  important  as  a 
 screening tool, for early detection of CD cases [1]. 
Serological tests can also be employed in the  follow-up 
and management of CD. Indeed, according to the 
ESPGAN criteria, when the diagnosis of CD is established 
by clinical, analytical, and histologic  studies,  repeated  
endoscopy with duodenal biopsy is not necessary if the 
patient’s condition improves after introducing a  gluten-
free  diet; the results of repeated endoscopy could be 
rather confusing, since normalization of the histology 
may  take up  to 8  years [44]. 
The serologic tests use highly specific antibody–
antigen interactions and are fundamental to identify the 
gluten intolerance and to monitor the response of the 
CD patients to a gluten-free diet [45]. There are two 
types of serologic tests. One detects the antibodies 
against the antigen gliadin (i.e., anti-gliadin antibodies 
(AGA)), in which the immu- noglobulin A (IgA) isotype 
is considered to be the most specific [46]; and the 
other, the autoantibody test, which detects IgA 
antibodies to tissue transglutaminase (IgA-tTG 
antibodies) and IgA endomysial antibodies (IgA-EMA) 
[18] that are usually present in serum during the active 
phase of CD [47]. However, some patients are IgA 
deficient and, therefore, in that case the detection of the 
pathology by the serological tests is jeopardized. 
Selective IgA deficiency affects about 2–5% of patients 
diagnosed with CD [48]. In these cases, the 
determination of the IgG class of antibodies against 
gliadin (IgG-AGA), endomysium (IgG-EMA), and tTG (IgG-
tTG antibodies) has been suggested as an alternative 
[47]. 
Since their description in 1958, AGA have been 
used as the serological markers for CD  [28].  Both  IgA  
and IgG AGA are present in the sera of patients with CD, 
although they lack specificity, as gliadin may cross the 
normal gut mucosa, being present in 5–10% of healthy 
population. 
Endomysium is a connective tissue protein found in 
the collagenous matrix of human and monkey tissue [3]. 
EMA association with CD was first described in 1984 [49] 
and its detection rapidly became the serological test of 
choice, due to its specificity of almost 100%. The use of 
human umbilical cord as substrate has been proposed 
as a valid alternative to the monkey esophagus [50–52]. 
Tissue transglutaminase (tTG) is a calcium-dependent 
enzyme expressed both intra- and extracellulary, and is 
implicated in physiologic processes like extracellular 
matrix (ECM) formation, cell adhesion, and apoptosis 
[53]. tTG serves as a cross-linker of different ECM 
proteins, resulting in the formation of an ε-(γ-glutamyl)–
lysine bond. Gliadin is the preferred substrate for tTG 
[3]. It was suggested that tTG has the ability to cross-link 
itself to gluten leading to antibody formation [54]. In 
1997 tTG was identified as the autoantigen recognized by 
the EMA [55] and was identified as the main autoantigen 
in  CD. 
  
 
Fig. 1 Proposed approach  for 
the evaluation of patients with 
suspected celiac disease [39, 
43] 
 
 
 
  
 
  
 
 
 
 
     
 
 
 
 
 
 
 
   
 
Sensitivity and specificity of serological markers 
 
The most sensitive and specific serologic markers of celiac 
disease are the IgA EMA and the tTG IgA antibodies [48]. 
While two different types of tests are  used  for  detect 
these autoantibodies, they detect antibodies to the same 
antigen, the tTG [56]. IgA anti-tTG antibody and IgA anti-
EMA tests have sensitivities higher than 90% and 
specificities higher than 95% and, therefore, the serolog- 
ical tests to detect those antibodies are recommended 
for initial screening [57]. In contrast, IgA AGA has a 
sensitivity of about 80%  and  a  specificity  ranging from 
80 to 90%. For routine diagnosis, the determination of 
gliadin antibodies in serum is no longer recommended, 
since they are less sensitive and specific than EMA and 
tTG antibody tests [43,  58]. 
IgG anti-EMA and anti-tTG antibodies, in spite of having 
a specificity rounding 95%, present poor sensitiv- ities 
(around 40%) and for this reason these antibodies have 
been used less frequently as serological markers [57]. 
However, because IgA deficiency has an increased preva- 
lence among celiac patients [29], care should be taken 
in interpreting the results of IgA antibody tests. In the case 
of IgA deficiency, measurement of IgG anti-EMA/tTG and 
IgG anti-gliadin antibodies should be performed. Positive 
results for IgA anti-EMA/tTG antibodies, or IgG anti-EMA/ 
tTG antibodies and AGA in the case of IgA deficiency 
should be followed by intestinal biopsy. A biopsy might 
also be recommended in cases of negative serology, when 
there is a high clinical suspicion. 
Clinical and/or histological improvement confirms the diagnosis of CD Start a gluten-free diet 
Confirmed the characteristic histological features of CD 
Test for IgG antibodies Positive results Small bowel biopsy 
Negative results: low probability of CD Positive results: high probability of CD 
IgA class tTG and/or EMA serological tests 
Suspicious of celiac disease 
(on a gluten containing diet) 
Remains clinical suspicion Patients with IgA deficiency 
 In positive serological cases, followed by a negative 
biopsy, it is important to consider HLA typing, since 
the absence of both HLA-DQ2 and/or HLA-DQ8 alleles 
has a very high negative predictive value, helping to rule 
out the disease in cases of equivocal biopsy results [3, 4,  
56]. 
It is established that the most widely used 
methodology for CD clinical serological diagnostic 
purposes is an enzyme-linked immunosorbent assay 
(ELISA). Several high-quality commercial kits are 
available to detect IgA antibodies to tTG and endomysial 
IgA antibodies, which appear to have equivalent 
diagnostic sensitivity and specificity. The advantages of 
tTG testing is that the ELISA test eliminates the 
disadvantages associated with the use of EMA, namely 
the higher cost, time-consuming protocol which is 
unsuitable for testing large numbers of samples, the use 
of monkey esophagus (or human umbilical cord), and 
the subjective interpretation of the immunofluorescence 
analysis [15]. Several studies have compared the 
analytical and clinical utility of commercially available 
anti- transglutaminase ELISAs assays [59–73], and found 
that the use of tTG as antigen for CD diagnosis 
presents an adequate sensitivity and specificity. 
Therefore, major efforts have been concentrated on 
developing a tTG-based ELISA, using either the 
commercially available guinea pig tTG or human 
recombinant tTG. 
The first-generation assays for tTG antibodies 
detection used guinea pig liver tTG as the antigen. 
Second-generation kits using purified human tTG or 
human recombinant tTG were developed and introduced 
in routine practice. Several studies compared the first- 
and second-generation kits  and 
   
 
 
 
concluded that the human antigens improve assay 
sensitiv- ity and selectivity [63, 74–76]. A third 
generation of kits using tTG–gliadin peptide complexes 
as the antigen has also been proposed; however, it 
seems to have no advantage over human recombinant 
antigen kits, especially regarding specificity [77, 78]. 
Several second-generation assays are commercially 
available, and were introduced in routine practice of 
clinical laboratories. These assays use either recombinant 
human tTG or purified human tTG as  antigen. 
Van Meensel [79] and colleagues evaluated 10 different 
commercially available second-generation IgA anti-tTG 
ELISA kits, and showed that most of these assays 
presented excellent performance, with good linear ranges. 
According to the optimal receiver operating 
characteristics (ROC) curve cutoff employed, the 
sensitivity values ranged from 91 to 97% and the 
specificity ranged between 96 and 100%. Since the areas 
under the ROC curve did not differ significantly, the 
results from using the kits could be compared; however, 
there is some variability between these immunosorbent 
assays which needs to be solved in order to reach higher 
homogeneity. 
 
Gluten-free food control 
 
Two guidelines concerning the management of CD were 
recently published: “Recommendations of NASPGHAN” 
[43] and “National Institutes of Health (NIH) consensus 
development conference statement on celiac disease” 
[80]. After a positive diagnosis for CD, the only 
treatment available, so far, is a lifelong strict adherence to 
a gluten- free diet, which will permit the recovery of 
the intestinal mucosa [18].  However,  a  diet  completely  
free  of gluten 
would be difficult, if not impossible, to  maintain. 
Gluten is a common component in the human diet, and 
its exclusion presents a big challenge for celiac disease 
patients. Gluten plays a key role in determining the 
unique baking quality of wheat by conferring water 
absorption capacity, cohesivity, viscosity, and elasticity to 
dough [81]. After sugar, it is perhaps the second most 
widespread food component in Western civilization [82]. 
Since about 10% of gluten seems to be made up of 
potentially toxic gliadin peptides [83] it is extremely 
important to evaluate the purity of gluten-free products to 
ensure a safe diet for celiac patients. To certify gluten-free 
products, the use of highly sensitive assays is mandatory. 
The European Union, World Health Organization, and 
Codex Alimentarius require reliable measurement of the 
wheat prolamins, gliadins, rather than all wheat-derived 
proteins [84]. There is still no general agreement on the 
analytical method to measure gluten in ingredients and 
food products [85], although the official limits described in 
the Codex Draft Revise Standard (2000) are 20 ppm for 
foodstuffs naturally gluten-free  and 
 200 ppm for foodstuffs rendered gluten-free [86]. 
Never- theless, to measure gluten traces in food, 
immunochemical methods are usually chosen to 
determine gliadins [87–92]. Besides the quality control 
of gluten-containing products, it is important to assess 
gluten in foodstuff that can be contaminated with 
native or heated proteins from wheat, barley, and rye. 
In recent years several analytical possibilities for the 
detection of the wheat protein component gliadin in 
food products have been exploited, such as the 
polymerase chain reaction (PCR) technology, mass 
spectrometry, or high- performance liquid 
chromatography (HPLC). PCR allows the amplification of 
a specific DNA fragment, flanked by two oligonucleotides 
that act as primers in the amplification reaction carried 
out by DNA polymerase. The amplified product is 
visualized by staining with a fluorescent dye or by 
Southern blotting after a gel electrophoresis. The 
amplification of gluten-specific DNA fragments by PCR 
has been reported [93, 94]. Normally, PCR results are 
only qualitative; however, by incorporating internal 
standards, the results provide semiquantitative 
measurements. By employing real-time PCR (rt-PCR) 
highly accurate quanti- tative results can be obtained. A 
quantitative competitive PCR system has been 
constructed, evaluated, and compared with ELISA, 
obtaining a good correlation of the results between the 
two methods [95]. In this study a wheat-, barley-, and 
rye-specific WBR11/WBR13 primer pair was used. These 
primers were also used in a quantitative competitive 
PCR system to detect gluten traces in flours and 
“gluten-free” bakery products [96]. Piknova and 
colleagues achieved detection limits of 200 mg/kg of 
wheat in flour using real-time PCR [97]. Henterich and 
colleagues performed a rt-iPCR (real-time immuno-
polymerase chain reaction (iPCR)) for the detection of 
the cereal protein gluten, gliadin. By using iPCR a 
detection limit of 16 mg gliadin/100 g food was 
achieved [98]. 
Matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry allows the 
detection of large proteins from highly complex protein 
mixtures such as those present in gluten prolamins [99]. 
The high resolution and sensitivity of this technique 
allow the elucidation of protonated molecular masses of 
most of the gliadin, hordein, secalin, and avenin 
components. Méndez and colleagues [100] concluded 
that the analysis of gliadin- containing foods by this 
technique allows the immediate identification of the 
characteristic gliadin mass pattern, consequently 
permitting easy identification of gliadins in such samples 
with a detection sensitivity of 50–100 ng total protein 
loaded. In another study a nonimmunological 
alternative to quantify gluten gliadins in food samples was 
presented [101]. The procedure allowed the 
microquantifi- cation of gluten in processed and 
unprocessed gluten- containing food samples below toxic 
levels for CD patients, 
  
 
 
with a linear response in the 0.4–10 mg per 100 g range 
and a detection sensitivity similar to that of ELISA systems. 
A new protocol for  determining  small  amounts  of 
gliadins in foods that contain relatively large amounts of 
other prolamin proteins from maize and/or rice was also 
described [102]. This strategy combines a two-step 
procedure of extraction (60%  aqueous  ethanol followed 
by 1 M acetic acid) with subsequent MALDI-TOF 
analysis to corroborate the presence of these ethanol- 
soluble wheat prolamin fractions. HPLC allows the 
separation and qualitative  and  quantitative 
determination of compounds of analytical interest. A 
widely used HPLC technique is reversed-phase high 
performance liquid chromatography (RP-HPLC). In 
reversed-phase systems, stationary phase is slightly polar 
or nonpolar, while mobile phase has stronger polarity. An 
RP-HPLC system has already been described for the 
separation and quantitative determination of wheat 
prolamins in food [103, 104]. Also a flow cytometry (FCM) 
method for the quantitative determination of picogram 
levels of gliadin was developed [105]. FCM is a high-
throughput technique that is able to analyze large 
numbers of cells individually using light- scattering and 
fluorescence measurements [106]. In the work by 
Capparrelli and colleagues [105], rat antibodies against a 
16-residue peptide of gliadin, common to the  α, β, γ, and 
ω-gliadins, were used. A detection limit under 10 pg/mL 
was  achieved. 
Despite the efforts in developing new analytical strate- 
gies for gluten control in foodstuffs, the most used 
method of measurement of gliadin still relies on the 
ELISA-like techniques. Thus, two commercial 
immunoassays are currently available to assess gluten 
content of gluten-free foods. The Association of 
Analytical Communities endorses the method originally 
developed by Skerritt and Hill [107], the sandwich ω-
gliadin ELISA, which uses a monoclonal antibody to the 
heat-stable ω-gliadin fraction. Since the ω-gliadin fraction 
is not denatured when heated for cooking or processing, 
this assay can be used to assess gluten content of foods 
containing both native and heated protein. One major 
drawback of this assay is that measure- ments of this 
subfraction with the extrapolation to total gliadin have 
theoretical errors of –44 to +80% [108]. Moreover it is 
unable to accurately detect and quantify barley prolamins 
and cannot accurately quantify hydrolyzed gluten [109]. 
The other test is the R5 ELISA [110] that has been 
proposed as the standard method for gluten analysis in 
gluten-free foods by  the  Codex  Committee  on Methods 
of Analysis and Sampling [111], promoted by the Codex 
Committee on Nutrition and Foods for Special Dietary 
Uses [112]. This test uses the R5 monoclonal antibody 
directed to the potentially celiac toxic epitope QQPFP 
(glutamine-glutamine-proline-phenylalaline-proline)    present 
 in wheat, rye, and barley prolamins. This immunoassay is 
able to quantify native and heated gluten although it 
seems to overestimate barley hordein [113] and to be 
unable to accurately quantify hydrolyzed gluten [109]. 
 
 
New strategies for celiac disease 
diagnosis and gluten-free food analytical  
control 
 
Currently, biosensor development is widespread in many 
fields and a considerable effort is being focused on the 
development of even more rapid, sensitive, high sample 
throughput, and, especially, on-site analytical strategies 
that can be applied in point-of-care analysis. Two kinds of 
sensors are found in the literature: optical and 
electrochemical. 
 
Optical biosensors 
 
De Stefano and colleagues [114] proposed the 
development of a porous silicon-based (PSi) optical 
biosensor for the detection of trace amounts of gliadin 
using a recombinant glutamine-binding protein (GlnBP) 
from Escherichia coli as a molecular probe. The 
solutions containing the molecular probe and the 
analyte, peptic-tryptic (PT)- gliadin, were directly spotted 
on the sensor surface. GlnBP was covalently linked to 
the surface of the PSi surface via a functionalization 
process. The proposed optical protein microsensor with 
a PSi-based transducer sensor allows a sensitive, fast, 
and easily readable optical response; moreover, it is 
able to work under reducing conditions, which solves 
some problems related to prolamin extraction. The 
results showed that about 45% of the spotted proteins 
had selectively bound the respective peptide. A fiber-
optic biosensor for the detection of anti-gliadin 
antibodies was also developed [115]. This biosensor was 
developed by coating a tapered optical fiber by 
immobilization  of gliadin using the electrostatic self-
assembly (ESA) method which allows the construction of 
nanometric-scale recog- nition surfaces on the fiber-
optic, allowing real-time monitoring of the sensor 
behavior. Gliadin antigens were successfully immobilized 
onto the surfaces of tapered optical fibers using the ESA 
method which has  been proved to be an efficient 
immobilization strategy. The biosensors were tested by 
using  antibodies  conjugated with and without 
peroxidase. A high  sensitivity  sensor was obtained, 
with fast response times as compared with standard 
ELISA tests. 
 
Electrochemical immunosensors 
 
Yet, the most commonly used biosensor strategy relies on 
electrochemical sensors. New electrochemical 
immunosen- sors (EIs), which employ cost-effective, user-
friendly,  and 
  
 
 
highly sensitive analytical transduction devices, have 
appeared as new exciting alternatives to the conventional 
immunochemical tests which are based on indirect detec- 
tion compromising real-time analysis. Electrochemical 
immunosensors are a self-contained integrated device 
that is capable of providing specific quantitative or 
semiquan- titative analytical information using an 
immobilized immu- nological recognition element (for 
detecting a target analyte by structural complementarity) 
and an electrochemical based-transducer which converts 
the biological interaction into a measurable signal [116]. 
Recently, two EIs for the detection of celiac disease 
toxic gliadin in foodstuffs were reported. Nassef and 
colleagues [117] developed an electrochemical immuno- 
sensing strategy for the detection of toxic gliadin using an 
antibody, coined CDC5, which was raised against the 
putative immunodominant celiac disease toxic epitope of 
α-gliadin, 56–75. For anchoring the captured  antibody, 
two different surfaces, based on a gold electrode 
modified with acidic self-assembled monolayers (SAMs), 
were proposed. A good performance regarding 
sensitivity, specificity, and reproducibility was 
obtained. When applied to real sample analysis an 
excellent performance correlation was achieved when 
compared with ELISA as well as considerable decrease in 
the time to perform the assay. In order to improve 
sensitivity, the use of antibody fragments instead of whole 
antibodies was also exploited. A new electrochemical 
immunosensor based on the spontaneous adsorption of 
anti-gliadin Fab fragments (CDC5-Fab) on gold surfaces 
was developed [118]. CDC5-Fab forms  a  stable  
monolayer  on  gold  after 15 min, which has long-term 
stability (2 months), when stored at 4 °C with more than 
90% of antigen recognition ability. By using 
amperometry to evaluate the ability of Fab-modified 
electrodes to detect gliadin a limit of detection of 3.29 
ng/mL was achieved. This Fab immu- nosensor has been 
shown to be highly sensitive, rapid, and simple and to 
have a short assay  time. 
Regarding clinical diagnosis of CD using EIs, some 
advances are also being achieved. Balkenhohl and Lisdat 
developed impedimetric immunosensors for the  
detection of antibodies directed against gliadin [119] and 
for the detection of autoantibodies against 
transglutaminase [120] in human serum.  The  
immunosensors  were based on the immobilization of 
gliadin and transglutaminase onto disposable screen-
printed gold electrodes which were covered with a 
polyelectrolyte layer of poly(sodium 4- styrenesulfonic 
acid). Although the results suggest a lower precision, as 
compared with ELISAs, an acceptable sensitivity was 
achieved, which makes the developed sensors reliable 
and promising methodologies for the analysis of anti-
transglutaminase and anti-gliadin antibodies in human 
serum. On the other hand, Pividori and colleagues 
 proposed an amperometric electrochemical 
immunosensor based on the physical adsorption of tTG 
from guinea pig liver onto graphite–epoxy composite 
(GEC) electrodes [121]. For 10 positive and 10 negative 
processed serum samples a sensitivity of 70% and a 
specificity of 100% were achieved, as compared with 
the commercial ELISA method. The developed sensor 
appears as a promising alternative to the conventional 
ELISA assays, as it is a simple, low cost, and point-of-care 
analytical method. The authors also proposed the 
evaluation of the benefits of transferring the developed 
methodology to disposable screen-printed electrodes. 
Although the immunosensor technology seems 
promis- ing, some limitations still remain, such as long-
term stability, surface effects, and interferences 
resulting from complex sample matrices. 
 
 
Conclusions 
 
The knowledge of celiac disease has grown in the last 
two decades and there has been a sharp increase in the 
number of newly diagnosed individuals. The different 
clinical presentations of CD can complicate the diagnosis 
and, therefore, delay the treatment of the disease. The 
advances in the efficacy of serological antibody testing 
potentiate the possibility of future accurate screening 
programmes in the community, working as a first-line 
method to clarify clinically suspicious cases in an 
underdiagnosed stage and also to manage the follow-up 
of this multifactorial disease. Patients with a low to 
moderate probability of presenting the disease should be 
submitted to blood studies rather than to small bowel 
biopsy. Several commercially available enzyme-linked 
immunoasorbent assay kits can be employed in CD 
screening. Among them, those using the serological 
markers IgA anti-tTG antibodies present the highest 
diagnostic accuracy. Although the overall diagnostic per- 
formance of the tests is good and similar for the 
different 
assays, greater standardization is required. 
After a positive diagnosis, the implementation of a 
gluten-free diet is the only treatment available for CD. 
Two immunological methods for gluten food analysis 
are commercially available, and both use monoclonal 
anti- bodies toward gluten proteins. Further studies are 
necessary to develop an analytical method that can 
discriminate and quantify the celiac-toxic polypeptides 
in food ingredients and processed foods. 
At the moment, ELISA assays are the recommended 
approach to the diagnosis of CD. Regarding gluten 
assessment in food products, ELISA R5 was provisionally 
endorsed by Codex Alimentarius, although there is not a 
standard methodology that receives universal agreement. 
There are several problems regarding the pretreatment    
of 
  
 
 
the food products which starts immediately with the 
extraction process. 
The need for a standardized methodology to perform 
an unequivocal clinical diagnosis of CD as well as to 
determine quantitatively the gluten content in food 
products with the gluten-free label still remains. 
 
 
Future perspectives 
 
Possible areas of future study may be  directed  toward 
new immunosensing strategies that combine the high 
specificity of traditional immunochemical methods with 
miniaturized systems that allow development of a 
point- of-care test for CD  clinical  diagnosis  and  gluten-
free food quality control. Nevertheless, the reference 
methods need to present better  international 
agreements, in   order to achieve a higher standardization 
for the different immunoassays. 
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